Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMMPOTCMKTS:JUSHFNASDAQ:LFCRNYSE:PRME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMMPImmutep$1.63-3.0%$1.71$1.32▼$3.34$238.04M1.94183,125 shs60,690 shsJUSHFJushi$0.34-2.2%$0.30$0.22▼$0.92$66.97M-0.62237,189 shs236,824 shsLFCRLifecore Biomedical$6.38+3.4%$6.19$3.68▼$7.99$236.22M0.8228,894 shs155,722 shsPRMEPrime Medicine$1.69-3.4%$1.89$1.12▼$8.27$221.66M1.881.21 million shs1.03 million shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMMPImmutep0.00%+5.84%-10.44%-17.05%-37.07%JUSHFJushi0.00%+6.44%+19.30%+5.45%-50.08%LFCRLifecore Biomedical0.00%-0.47%-6.59%+0.95%+0.79%PRMEPrime Medicine0.00%+36.29%-15.50%-46.35%-64.04%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMMPImmutep1.6859 of 5 stars3.53.00.00.02.20.00.0JUSHFJushi0.6128 of 5 stars0.04.00.00.00.01.70.6LFCRLifecore Biomedical2.181 of 5 stars3.21.00.00.02.73.30.6PRMEPrime Medicine2.4606 of 5 stars3.60.00.00.01.63.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMMPImmutep 3.00Buy$8.50421.47% UpsideJUSHFJushi 1.50ReduceN/AN/ALFCRLifecore Biomedical 2.33Hold$8.0025.39% UpsidePRMEPrime Medicine 3.11Buy$13.38691.42% UpsideCurrent Analyst Ratings BreakdownLatest JUSHF, IMMP, PRME, and LFCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/20/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $16.003/19/2025PRMEPrime MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/18/2025PRMEPrime MedicineWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$12.00 ➝ $13.003/3/2025PRMEPrime MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/3/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.002/28/2025PRMEPrime MedicineWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$12.00(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMMPImmutep$5.14M46.31N/AN/A$1.05 per share1.55JUSHFJushi$269.45M0.25N/AN/A($0.04) per share-8.52LFCRLifecore Biomedical$130.86M1.81N/AN/A$0.37 per share17.24PRMEPrime Medicine$2.98M74.31N/AN/A$1.37 per share1.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMMPImmutep-$28.01MN/A0.00N/AN/AN/AN/AN/AN/AJUSHFJushi-$65.10M-$0.24N/AN/AN/A-20.93%N/A-10.45%5/8/2025 (Estimated)LFCRLifecore Biomedical$12.01M-$1.45N/AN/AN/A-12.52%-315.23%-12.74%N/APRMEPrime Medicine-$198.13M-$1.65N/AN/AN/AN/A-107.87%-74.97%N/ALatest JUSHF, IMMP, PRME, and LFCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025N/AJUSHFJushi-$0.06N/AN/AN/A$66.23 millionN/A4/3/2025Q3 2025LFCRLifecore Biomedical-$0.14-$0.19-$0.05-$0.47$33.23 million$35.15 million3/12/2025Q4 2024JUSHFJushi-$0.04-$0.06-$0.02-$0.06$64.03 million$65.86 million3/7/2025Full YearPRMEPrime MedicineN/A-$1.65N/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMMPImmutepN/AN/AN/AN/AN/AJUSHFJushiN/AN/AN/AN/AN/ALFCRLifecore BiomedicalN/AN/AN/AN/AN/APRMEPrime Medicine$1.4585.56%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMMPImmutep0.0118.2518.25JUSHFJushiN/A1.170.58LFCRLifecore Biomedical9.212.321.21PRMEPrime MedicineN/A6.506.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMMPImmutep2.32%JUSHFJushi21.68%LFCRLifecore Biomedical83.36%PRMEPrime Medicine70.37%Insider OwnershipCompanyInsider OwnershipIMMPImmutep3.07%JUSHFJushi21.66%LFCRLifecore Biomedical32.20%PRMEPrime Medicine23.47%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMMPImmutep2,021146.04 million141.09 millionOptionableJUSHFJushi1,188196.63 million154.04 millionNot OptionableLFCRLifecore Biomedical69037.03 million26.58 millionOptionablePRMEPrime Medicine234131.16 million100.38 millionOptionableJUSHF, IMMP, PRME, and LFCR HeadlinesRecent News About These CompaniesPrime Medicine: Initiating Coverage At Hold With 2025 Binary Catalyst For PM359April 26 at 7:32 AM | seekingalpha.comWhy Prime Medicine, Inc.’s (PRME) Stock Is Down 5.43%April 26 at 7:32 AM | aaii.comPrime Medicine, Inc. (NYSE:PRME) Shares Bought by Walleye Capital LLCApril 22, 2025 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Given Average Rating of "Buy" by BrokeragesApril 20, 2025 | americanbankingnews.comPrime Medicine, Inc. (NYSE:PRME) Given Consensus Rating of "Buy" by AnalystsApril 16, 2025 | marketbeat.comPrime Medicine Stock Price, Quotes and ForecastsApril 13, 2025 | benzinga.comWhy Prime Medicine, Inc.’s (PRME) Stock Is Down 12.42%April 5, 2025 | aaii.comWhy Prime Medicine, Inc.’s (PRME) Stock Is Down 10.30%April 2, 2025 | aaii.comPrime Medicine price target raised to $16 from $15 at ChardanMarch 20, 2025 | markets.businessinsider.comWhy Prime Medicine Stock Was Climbing Higher This WeekMarch 20, 2025 | fool.comPrime Medicine Advances AATD Program With Prime Editing For Potential Curative TreatmentMarch 20, 2025 | nasdaq.comWhy Prime Medicine Stock Is Soaring TodayMarch 19, 2025 | fool.comPrime Medicine, Inc.: Promising Future in Gene Editing with Innovative AATD Program and Strategic Growth PotentialMarch 19, 2025 | tipranks.comPrime and Beam, born of same lab, pursuing rival gene-editing treatmentsMarch 19, 2025 | statnews.comPrime Medicine unveils program for treatment of AATDMarch 18, 2025 | markets.businessinsider.comPrime Medicine, Inc.: Innovative Prime Editing Technology and Promising Preclinical Results Drive Buy RatingMarch 18, 2025 | tipranks.comPrime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)March 18, 2025 | globenewswire.comPrime Medicine, Inc.: Strategic Advancements and Promising Financial Outlook Drive Buy RatingMarch 18, 2025 | tipranks.comJ.P. Morgan Reaffirms Their Buy Rating on Prime Medicine, Inc. (PRME)March 4, 2025 | markets.businessinsider.comPrime Medicine Reports 2024 Financial Results and ProgressFebruary 28, 2025 | tipranks.comPrime Medicine, Inc.: Prime Medicine Reports Full Year 2024 Financial Results and Provides Business UpdatesFebruary 28, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJUSHF, IMMP, PRME, and LFCR Company DescriptionsImmutep NASDAQ:IMMP$1.63 -0.05 (-2.98%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$1.70 +0.07 (+3.99%) As of 04/25/2025 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.Jushi OTCMKTS:JUSHF$0.34 -0.01 (-2.24%) As of 04/25/2025 03:58 PM EasternJushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for medical and adult-use markets. The company offers flower, extracts, concentrates, edibles, oil, pre-rolls, tinctures, capsules, softgels, cannabis-infused gummies and ultra-premium chocolate, and topicals products, as well as vaporization devices and cartridges under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands. It is also involved in the bulk wholesale of refined cannabinoids and terpenes. In addition, the company operates medical cannabis dispensaries under the BEYOND/HELLO, Nature's Remedy, and NuLeaf brands. It markets its products to local dispensaries and large multi-state operators. The company is headquartered in Boca Raton, Florida.Lifecore Biomedical NASDAQ:LFCR$6.38 +0.21 (+3.40%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$6.38 0.00 (-0.08%) As of 04/25/2025 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.Prime Medicine NYSE:PRME$1.69 -0.06 (-3.43%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$1.71 +0.02 (+1.18%) As of 04/25/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
